Healthcare provider profile · identity verified

Alison Purcell, CRNP

Nurse Practitioner · PHILADELPHIA, PA · NPI 1487940193

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	187	63
Amlodipine Besylate	Amlodipine Besylate	141	48
Fluticasone Propionate	Fluticasone Propionate	133	46
Albuterol Sulfate Hfa	Albuterol Sulfate	99	39
Rosuvastatin Calcium	Rosuvastatin Calcium	93	28
Omeprazole	Omeprazole	87	27
Trulicity	Dulaglutide	83	21
Hydrochlorothiazide	Hydrochlorothiazide	81	28
Metformin Hcl Er	Metformin Hcl	71	21
Gabapentin	Gabapentin	56	19
Metformin Hcl	Metformin Hcl	47	16
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	46	14
Carvedilol	Carvedilol	46	13
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	46	18
Azelastine Hcl	Azelastine Hcl	45	13
Tizanidine Hcl	Tizanidine Hcl	43	suppressed
Famotidine	Famotidine	42	13
Diclofenac Sodium	Diclofenac Sodium	41	14
Losartan Potassium	Losartan Potassium	41	14
Ozempic	Semaglutide	40	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	38	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	11
Mounjaro	Tirzepatide	37	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	36	suppressed
Lisinopril	Lisinopril	35	17
Sertraline Hcl	Sertraline Hcl	34	suppressed
Varenicline Tartrate	Varenicline Tartrate	34	suppressed
Allopurinol	Allopurinol	32	12
Montelukast Sodium	Montelukast Sodium	32	suppressed
Pravastatin Sodium	Pravastatin Sodium	32	suppressed
Oxycodone Hcl	Oxycodone Hcl	31	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	30	suppressed
Metoprolol Succinate	Metoprolol Succinate	29	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	29	12
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	29	suppressed
Eliquis	Apixaban	28	suppressed
Valsartan	Valsartan	28	suppressed
Furosemide	Furosemide	27	suppressed
Naproxen	Naproxen	27	suppressed
Potassium Chloride	Potassium Chloride	27	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	26	12
Finasteride	Finasteride	26	suppressed
Tramadol Hcl	Tramadol Hcl	26	suppressed
Celecoxib	Celecoxib	25	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Trazodone Hcl	Trazodone Hcl	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	23	suppressed
Ketoconazole	Ketoconazole	22	suppressed
Latanoprost	Latanoprost	22	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	22	suppressed
Jardiance	Empagliflozin	21	suppressed
Lidocaine	Lidocaine	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	20	suppressed
Hydrocortisone	Hydrocortisone	19	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	18	suppressed
Alendronate Sodium	Alendronate Sodium	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Ammonium Lactate	Ammonium Lactate	14	suppressed
Divalproex Sodium Er	Divalproex Sodium	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Clotrimazole	Clotrimazole	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Loperamide	Loperamide Hcl	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Prednisone	Prednisone	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error